Tinkering with the vasopressin pathway in autism

Sci Transl Med. 2019 May 8;11(491):eaax7315. doi: 10.1126/scitranslmed.aax7315.

Baudouin Forgeot d'Arc^{1

2

3}, Laurent Mottron^{2

3}, Mayada Elsabbagh^{4

5}, Sébastien Jacquemont^{1

6}

¹ CHU Sainte-Justine Research Center, Montréal, Quebec H3T 1C5, Canada. sebastien.jacquemont@umontreal.ca b.forgeot@gmail.com.
² Department of Psychiatry, Université de Montréal, Montréal, Quebec H3C 3J7, Canada.
³ Centre intégré Universitaire du Nord-de-l'Île-de-Montréal, Montréal, Quebec H1E 1A4, Canada.
⁴ McGill University, Montréal, Quebec H3A 0G4, Canada.
⁵ Montreal Neurological Institute, Montréal, Quebec H3A 2B4, Canada.
⁶ Department of Pediatrics, Université de Montréal, Montréal, Quebec H3C 3J7, Canada.

Abstract

Two clinical trials targeting the vasopressin pathway in autism highlight continuing challenges in outcome measures and statistical power.